Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

OBJECTIVE: Assess the effect of abatacept on progression of structural damage over 2 years in patients with rheumatoid arthritis who had an inadequate response to methotrexate. METHODS: 539 patients entered an open-label extension of the AIM (Abatacept in Inadequate responders to Methotrexate) trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Genant, H K, Peterfy, C G, Westhovens, R, Becker, J-C, Aranda, R, Vratsanos, G, Teng, J, Kremer, J M
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Extended Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569144/
https://www.ncbi.nlm.nih.gov/pubmed/18086727
http://dx.doi.org/10.1136/ard.2007.085084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569144/
https://www.ncbi.nlm.nih.gov/pubmed/18086727
http://dx.doi.org/10.1136/ard.2007.085084

Ejemplares similares